Vitalik Buterin has published an updated long-term roadmap for Ethereum, calling the multi-year effort "Lean Ethereum" as the network's biggest redesign since ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

In the latest legal setback for LGBTQ+ Americans, the Supreme Court said Colorado’s ban on LGBTQ+ “conversion therapy” for young people infringes on the free speech rights of a Christian counselor.

Insights, news and analysis of the crypto market straight to your inbox ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

A product launch can feel like a finish line, but in most tech organizations, it’s really the start of the next job: refining the solution to ensure it has staying power. Once customers start clicking ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals uses AI to develop drugs. The company's goal is to improve and speed up a process that is slow, expensive, and risky. Most medicines that enter the clinic never make it to ...